Skip to main content

Deal Alert: ChrysCapital invests Rs.300-Cr in Intas Pharma

Image
By
From the Press Release:

Ahmedabad-based Intas Pharma, one of India’s leading private pharmaceutical companies, today announced that it is raising Rs. 300 crores from ChrysCapital in a pre-IPO round.  The Company has deferred its listing plans for the time being and intends to re-file for an IPO once market conditions stabilize.

Intas is an established global pharmaceutical player with FY 2012 revenues of over Rs. 2,700 crores.  The Company has a strong presence in chronic therapy areas and is currently ranked 12th in the domestic market by ORG-IMS.  Intas also has a fast growing and significant export base in Europe and USA under the brand name of Accord Healthcare.

This will be ChrysCapital’s second investment in Intas, having originally backed the Company in 2006 from an older fund.  As an existing investor in the Company, ChrysCapital has benefited significantly from the strong performance recorded by Intas over the past six years.  Consequently, this investment comes at a significant multiple to the 2006 investment.

Based on the Chairman, Hasmukh Chudgar’s recommendation, the Board of Directors endorsed the appointments of Binish Chudgar as the Vice-Chairman & MD and Nimish Chudgar as the MD & CEO with immediate effect. These appointments are to drive forward the Company’s ambitious growth plans and develop world-class leadership in the run-up to a public listing in the near future.

Binish Chudgar of Intas commented, “ChrysCapital has been an integral part of our journey and has played an important role in determining our business strategy along the way.  We greatly value ChrysCapital as an investment partner and look forward to extending our association further.”

Sanjiv Kaul, ChrysCapital’s nominee on the board of the Company, said, “Intas has demonstrated impressive historical growth and profitability and is poised for significant growth in the years ahead.  The Company has gained market share in a fast growing domestic market and successfully scaled up its international business at the same time.  This follow-on investment reaffirms ChrysCapital’s faith in the Company’s ability to continue to deliver superior shareholder value over the years.”

About Intas Pharmaceuticals Limited
Intas is a leading, vertically integrated Indian pharmaceutical company engaged in the development, manufacture and marketing of formulations including bio-pharmaceuticals. In the domestic market, the Company has over 55% of its revenues coming from chronic therapy areas like cardio and central nervous system.  Internationally, Intas is present in over 50 countries worldwide predominantly in North America, Europe & Latin America with exports constituting around 40% of total revenues. The Company operates 10 manufacturing facilities with approvals from leading regulatory agencies like the USFDA.

About ChrysCapital
ChrysCapital manages $2.5 billion across six funds and is one of the leading private equity funds that invest in India. With 60 investments since 1999, ChrysCapital has valuable experience in evaluating investment opportunities across a breadth of sectors that leverage growth in the Indian economy.

For further information, please contact:
Binish Chudgar, Vice-Chairman & Managing Director, Intas Pharma
Tel: 079 – 2657 6655
E-mail: binish_chudgar@intaspharma.com

Jayesh Shah, CFO, Intas Pharma
Tel: 91-9998050507
E-mail: jayesh@intaspharma.com

Popular posts from this blog

EY Tops League Table for Transaction Advisors to M&A deals in 24

By
Moelis & Company & PwC claim the No.2 & No.3 slots Ernst & Young  (EY) topped the Venture Intelligence League Table for Transaction Advisor to M&A Deals   during 2024, advising 34 deals worth $4.1 Billion. Moelis & Company stood second advising 2 deals worth $3.9 billion. PwC followed with 18 deals worth $3.3 billion. Citi ($2.5 billion across 1 deal) and Advay Capital ($2.3 billion across 1 deal) completed the top five. Among the largest M&A deals in 2024, Citi  advised $2.5 Billion acquisition of the Indian business of American Tower Corporation by Brookfield , Advay Capital and Moelis & Company advised the $2.3 Billion acquisition of Care Hospitals by Aster DM Healthcare . Jefferies & Co., JP Morgan and Moelis & Company advised the $1.6 Billion acquisition of Bharat Serums & Vaccines by Mankind Pharma.  Among the other notable M&A deals in Q4 2024, EY advised the $685 million acquisition of ITD Cementation ...
Read more

Morgan Stanley tops League Table for Transaction Advisors to M&A deals in 2020

By
Morgan Stanley , which advised the $10.1 Billion strategic investment by Facebook and Google into Reliance Industries' telecom arm Jio platforms (among other Private Equity investments in the company), topped the Venture Intelligence League Table for Transaction Advisor to M&A Deals for 2020. Ambit Corporate Finance - which advised 3 deals worth $4.0 Billion, including Brookfield's $3.7 Billion acquisition of Reliance Tower Infrastructure Trust -  took the second spot. JM Financial ($3.7 Billion across 5 deals), Metta Capital ($3.4 Billion across 3 deals) and ICICI Securities ($3.4 Billion across 2 deals) - all of whom (along with Citi) are advisors to the $3.4 Billion acquisition of Future Group's retail related ventures by Reliance Retail, announced in August - completed the top five. The  Venture Intelligence League Tables , the first such initiative exclusively tracking transactions involving India-based companies, are based on the value of PE and M&A tra...
Read more

Everything you wanted to know (and some things you didn't care to know) about ChrysCapital's Ashish Dhawan

By
New Delhi-based private equity fund ChrysCapital is vastly different from its former avatar, Chrysalis Capital. While Chrysalis began life (in Mumbai) as an venture capital firm focussed on start-up investments, today's ChrysCapital is best know for its late-stage investments (often in already public companies). The fascinating part of this transformation is that one of the fund's original partners - Senior Managing Director Ashish Dhawan - has been firmly in the driver's seat throughout the process. It's a story that needed to be told. As a cover story. Kudos to Business Today for telling it first. Thankfully, unlike the glowing profiles that BT is famous for - including the one featuring infamous stock brocker Harshad Mehta with his Lexus on the cover - this one has a lot of facts. Some well known. And others less so. That ChrysCapital's first fund would have been a disaster but for the pioneering investment in Raman Roy founded BPO firm Spectramind i...
Read more

Why did Sony Entertainment Television's CEO quit?

By
Businessworld has a cover story on the corporate battle that resulted in Kunal Dasgupta, the CEO of Multi Screen Media (formerly Sony Entertainment Television), quitting just a few months before his contract was due to end. Dasgupta’s abrupt exit was the culmination of six years of tension between majority shareholder Sony Pictures Television International (SPTI) that owns 61 per cent of MSM, on one hand, and Atlas Equifinn on the other, which is a consortium of Indian shareholders (Singapore-based Rakesh Aggarwal, World Media Group director Sudesh Iyer, Shemaroo Entertainment Managing Director Raman Maroo, MobiApps Holding’s Jayesh Parekh, B.R. Sule, Sushil Shergil and actor Jackie Shroff ) holding 32 per cent. Capital Japan and some financial institutions own the rest 7 per cent. And of course, the third protagonist is Dasgupta, who walked a tightrope and managed to keep his job for over 14 years despite the fact that neither group of shareholders was too happy with him. Very little...
Read more

APEX VC Awards: Chiratae Ventures, Blume Ventures, Elevation Capital, Stride Ventures & Alteria Capital judged best funds of 2021

By
Press Release Elevation Capital , Chiratae Ventures , Blume Ventures , Stride Ventures and Alteria Capital were voted the top Venture Capital investors in India during 2021. The Venture Intelligence “Awards for Private Equity Excellence” (APEX) is dedicated to celebrating the best that the Indian Private Equity & Venture Capital industry has to offer. "VCs exist because Entrepreneurs exist and disrupt the ecosystem by creating new businesses. We are very excited to be part of the secular trend of tech disruption that would power India’s journey towards $ 10 Trillion economy over the next decade," said  T C Meenakshi Sundaram, Founder & Vice Chairman, Chiratae Ventures , winner of " VC Fund raise of the Year " award.  " We wish to thank all our entrepreneurs who have chosen to take funding from Chiratae Ventures and investors who have backed us with funds over the past 15 years in this journey.  Congratulations to the entire Chiratae Ventures team and ...
Read more